Dermatologie (Heidelberg, Germany) · 2026
[Acute venous disorders: deep vein thrombosis and superficial vein thrombosis of the lower extremity : Diagnosis and treatment in dermatology practice].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prien Lara Maria, Mitschang Carolin, Goerge Tobias
Аннотация
BACKGROUND: Deep vein thrombosis (DVT) is associated with potentially serious complications such as pulmonary embolism (PE) and postthrombotic syndrome. Superficial vein thrombosis (SVT) is also clinically relevant, as concomitant DVT and/or PE may already be present at initial diagnosis or may develop during follow-up.
OBJECTIVE: Which diagnostic and therapeutic steps are most relevant for dermatologists in clinical practice?
METHODS: Overview of the German S2k guideline and selected literature, supplemented by two case vignettes.
RESULTS: DVT diagnostics are guided by clinical pretest probability (Wells score). In patients with low probability, a negative D‑dimer test can rule out DVT. In patients with high probability or a positive D‑dimer test, duplex compression ultrasonography is indicated. In confirmed DVT, prompt therapeutic anticoagulation is required, preferably with direct oral anticoagulants, usually for ≥ 3 months depending on provocation status and risk of recurrence. In SVT, thrombus length and proximity to the deep venous junction determine management. SVT ≥ 5 cm, marked symptoms, or relevant risk factors warrant 45 days of anticoagulation (e.g., fondaparinux 2.5 mg s.c. once daily). SVT < 3 cm from the junction or with progression into the deep venous system requires therapeutic-dose anticoagulation analogous to DVT. Short-segment distal SVT can often be managed symptomatically.
CONCLUSION: Structured risk stratification, focused diagnostic work-up, and guideline-concordant therapy are essential to prevent thromboembolic complications.
OBJECTIVE: Which diagnostic and therapeutic steps are most relevant for dermatologists in clinical practice?
METHODS: Overview of the German S2k guideline and selected literature, supplemented by two case vignettes.
RESULTS: DVT diagnostics are guided by clinical pretest probability (Wells score). In patients with low probability, a negative D‑dimer test can rule out DVT. In patients with high probability or a positive D‑dimer test, duplex compression ultrasonography is indicated. In confirmed DVT, prompt therapeutic anticoagulation is required, preferably with direct oral anticoagulants, usually for ≥ 3 months depending on provocation status and risk of recurrence. In SVT, thrombus length and proximity to the deep venous junction determine management. SVT ≥ 5 cm, marked symptoms, or relevant risk factors warrant 45 days of anticoagulation (e.g., fondaparinux 2.5 mg s.c. once daily). SVT < 3 cm from the junction or with progression into the deep venous system requires therapeutic-dose anticoagulation analogous to DVT. Short-segment distal SVT can often be managed symptomatically.
CONCLUSION: Structured risk stratification, focused diagnostic work-up, and guideline-concordant therapy are essential to prevent thromboembolic complications.